Coverage
-
June 15, 2020
A Manhattan federal judge on Monday slashed nearly $88 million from a $157.5 million fee award requested by Garwin Gerstein & Fisher LLP and five other firms for guiding wholesalers of the Alzheimer's drug Namenda to a $750 million antitrust settlement with a unit of Allergan PLC.
18 other articles on this case.
View all »